Evidence map›Paper›PMID 31782039›Full record

ArticleMetabolic brain disease2020

Stroke-like episodes in OPA1 carriers require comprehensive work-up and therapeutic considerations.

Josef Finsterer

Abstract readLetter
PubMed Publisher
In one paragraph

Article in Metabolic brain disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Josef FinstererKrankenanstalt Rudolfstiftung, Messerli Institute, Postfach 20, 1180, Vienna, Europe, Austria. fifigs1@yahoo.de.ORCID http://orcid.org/0000-0003-2839-7305

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This is a letter to the Editor concerning the recently published article by Zerem et al. The paper described a 12yo female with multisystem mitochondrial disorder (MID) due to the compound heterozygous variants c.1963_1964dupAT and p.Ile382Met in OPA1 manifesting phenotypically with congenital nystagmus, developmental delay, visual impairment, gait ataxia, epilepsy, a stroke-like episode (SLE) with encephalopathy and vomiting, and hearing impairment. This interesting case could be more meaningful by providing more information about the treatment of the SLE/stroke-like lesion (SLL), about the morphological characteristics of the SLL on MRI, and the results of prospective investigations for subclinical involvement of organs so far clinically unaffected.

Indexed as

HeterozygoteAnticonvulsantsChildFemaleGTP PhosphohydrolasesHumansMitochondrial DiseasesNeurologic ExaminationStrokeAnticonvulsantsGTP PhosphohydrolasesOPA1 protein, humanMitochondrial disorderMultiorganOptic atrophyOxidative phosphorylationRespiratory chainStroke-like episode

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.